23andMe Pitch Deck: Slide-by-Slide Breakdown

The Strategic Pivot: From Ancestry to Antibodies

The 23andMe investor presentation is a sophisticated document designed to move the investor's perception of the company from a 'one-time kit sale' business to a 'recurring data and therapeutics' powerhouse. At 47 slides (24 analyzed here), it provides a comprehensive look at how a consumer brand can leverage its user base to enter the highly regulated and high-stakes world of drug development.

The Executive Team and Vision

Slide 1 & 2: The presentation opens with a clean, branded title slide followed immediately by the key leadership. The inclusion of Evan Lovell (Virgin Group) alongside Anne Wojcicki (CEO), Steve Schoch (CFO), and Kenneth Hillan (Head of Therapeutics) signals the merger's significance. The visual theme of chromosomes at the bottom of the slides reinforces the core scientific identity of the brand.

Slide 4: This slide sets the 'Problem' stage. It characterizes the U.S. healthcare system as 'dysfunctional,' citing that 25% of spending is waste and the probability of drug success is less than 12%. By framing the industry's failure in terms of cost ($2.6B to develop a drug) and time (10 years), 23andMe prepares the audience for its 'Solution': a more efficient, data-driven approach.

Pioneering D2C Healthcare

Slide 6: 23andMe stakes its claim as the pioneer of digital D2C healthcare. It highlights its history of FDA authorizations, starting with Carrier Status in 2015 and moving through BRCA (2017) to Pharmacogenetics in 2020. This timeline is crucial for establishing regulatory credibility, an area where the company famously struggled in its early years.

Slide 8: The 'World Class Leadership' slide is a 'who's who' of tech and biotech. It lists experience from Facebook, Netflix, Amgen, Genentech, and Google. This mix of consumer tech and deep-science expertise is presented as a competitive advantage that traditional pharma companies lack.

The Data Flywheel

Slide 9 & 11: The presentation defines the core of the business as a 'big data problem.' Slide 11 introduces the 'Consumer Powered Healthcare Flywheel.' This is the most important conceptual slide in the deck. It shows how 10.7 million genotyped customers and 30k+ daily surveys feed into a research loop of phenotypic and genetic data. This loop produces insights that lead to both 'Drug Discoveries' and 'Novel Consumer Products,' which then return value to the customer, encouraging more data sharing.

Slide 13: To humanize the data, the deck uses a case study of 'Ann M.,' a customer who discovered a BRCA1 mutation through 23andMe despite not meeting traditional clinical guidelines for testing. This slide argues that 23andMe catches risks that the traditional healthcare system misses, specifically noting that 80% of people with the mutation are 'missed by the healthcare system.'

Engagement and Subscription

Slide 15: This slide focuses on the 'Meaningful, Engaging (and Fun) Experience.' It boasts that 80% of customers consent to research and that 60% of even their oldest customers (pre-2015) logged in during 2020. This high engagement is the 'moat' that allows for longitudinal data collection.

Slide 17: Here, the company introduces 23andMe+, its subscription service. This represents a shift toward recurring revenue. The service offers pharmacogenetics, heart health reports, and polygenic risk scores. By moving into 'Proactive' health management (Slide 19), 23andMe positions itself as a lifelong health partner rather than a one-off ancestry report.

Therapeutics: The Value Driver

Slide 21 & 22: Section 3 shifts entirely to therapeutics. Slide 22 presents a direct comparison between the 'Pharmaceutical Industry' and '23andMe.' It claims 23andMe can reach the IND (Investigational New Drug) stage in ~4 years compared to the industry average of 7 years, while doubling the probability of success. This is a bold claim backed by a 2015 Nature publication on the support of human genetic evidence.

Slide 24: This slide shows the power of scale. A graph demonstrates that the number of independent genetic 'hits' (potential drug targets) increases linearly as the database grows. This justifies the constant push for more consumer kit sales; every new customer makes the drug discovery engine more powerful.

Slide 26: The GSK collaboration is detailed here. With a $300M investment and 30+ joint programs, GSK provides the clinical and commercial infrastructure that 23andMe lacks. This partnership validates 23andMe's data in the eyes of institutional investors.

Slide 28: The deck highlights its lead program, CD96, an immuno-oncology target. It shows how ML and AI were used to identify a genetic signature that mirrors successful I/O drugs like Keytruda. This is the 'proof of concept' for their entire therapeutic strategy.

Financials and Projections

Slide 30 & 31: The company shows rapid scaling in validated targets, projecting a move from 2 targets in FY19A to 37 in FY24E. Slide 31 shows cumulative genotyped customers reaching 11.2 million by FY21E, while also noting that Customer Acquisition Cost (CAC) is a significant part of the investment.

Slide 33: Future growth drivers are split between 'Consumer Opportunity' (kits and subscribers) and 'Therapeutics' (validated targets). The projection of 2.9 million subscribers by FY24E is a key metric for valuation, as subscription revenue typically carries higher multiples than hardware/kit sales.

Slide 35: The TAM (Total Addressable Market) slide is massive, citing $250B for Telehealth, $825B for Prescription Drugs, and $190B for Pharma R&D. By connecting their 10M+ customers to these markets, 23andMe justifies a multi-billion dollar valuation.

Slide 36 & 39: The transaction overview confirms the $3.5 billion enterprise value. However, the 'Adjusted EBITDA Reconciliation' on Slide 39 shows the cost of this growth: a net loss of $251 million in FY20A. The company is clearly in a 'burn for growth' phase, reinvesting heavily in R&D and customer acquisition.

What 23andMe Does Well

Narrative Bridge: The deck successfully bridges the gap between a consumer 'fun' product and a 'serious' biotech company. It uses the consumer data as the 'unfair advantage' for the biotech side. · Regulatory Proof: By listing specific FDA authorizations, they neutralize the historical concern that their tests aren't 'real' medicine. · Scale as a Moat: They effectively argue that their database is a proprietary asset that cannot be easily replicated, even by big pharma. · Strategic Partnerships: The GSK slide is a massive credibility booster. It shows that one of the world's largest pharma companies is willing to bet $300M on their data.

What is Missing from the Deck

Unit Economics: While they mention CAC on Slide 31, they do not provide a clear breakdown of the Lifetime Value (LTV) of a customer or the gross margins on the kits themselves. · Competition: There is no mention of competitors like Ancestry.com or newer, more clinical-focused genetic testing companies. The deck acts as if 23andMe exists in a vacuum. · Privacy and Security: Given the sensitivity of genetic data, the lack of a dedicated slide on data security and privacy (beyond a brief mention of 'consent') is a notable omission for a public-facing document. · Path to Profitability: The EBITDA slide shows deepening losses, but there is no clear 'break-even' projection provided in the analyzed slides.

What Other Founders Can Copy

The Flywheel Graphic: Slide 11 is a perfect example of how to show multiple business units supporting each other. If your startup has a B2C and a B2B side, show how they feed each other. · Humanizing Data: Using 'Ann M.' (Slide 13) to explain a complex genetic concept makes the technology relatable and demonstrates real-world impact. · Comparative Benchmarking: Slide 22, which compares 23andMe's metrics against the 'Pharmaceutical Industry,' is a great way to show disruption. Founders should always find an industry standard to beat. · Visual Consistency: The use of the chromosome motif and a consistent color palette makes the 47-slide deck feel cohesive and professional.